GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression ...

Shares of Gritstone bio Inc. (GRTSQ) have been struggling lately and have lost 87.3% over the past four weeks. However, a ...

Gritstone also has a vaccine for KRAS-driven tumors in Phase 2 development. The company is also developing an HIV vaccine with Gilead Sciences ( GILD ), according to its website. More on Gritstone bio ...

Two dozen firms looked at the company before it filed for bankruptcy protection. Leaders of Gritstone Bio Inc. could read the writing on the wall: Financial times for drug developers are tough and ...

Gritstone Oncology ( (GRTS)) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has voluntarily filed for Chapter 11 bankruptcy to restructure and preserve ...

Gritstone's candidate is a self-amplifying messenger RNA vaccine (samRNA), which uses a slightly different technology to the mRNA-based jabs from Pfizer/BioNTech and Moderna.

This is a summary of a request from Gritstone bio to hire Fenwick & West as special corporate counsel, filed Oct. 23 with the U.S. Bankruptcy Court in Delaware.

EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to ...

Across the recent three months, 4 analysts have shared their insights on Gritstone Bio (NASDAQ:GRTS), expressing a variety of opinions spanning from bullish to bearish. The following table ...

Northern Gritstone, the new investment business focused on university spin-outs in the north of England, today announces a first close of £215m having seen strong interest from investors in its ...

Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it has ...